1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Financial Assessment of the Global Pharmaceutical and Biotechnology Industry 

Financial Management is the Key Strategy for Sustainability

This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.

The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include:

•The global economic slowdown
•Regulatory compliance
•Reducing profitability
•Increasing R&D costs
•Pricing pressures
•Counterfeit business

Financial Analysis of the Pharmaceutical and Biotechnology Industry

1. Margin Analysis
•The pharmaceutical industry has generally witnessed smaller margins due to increasing competition from generics, pricing pressures, and decreasing healthcare spending.
•In the biotechnology industry, companies within low revenue range and relatively new products have witnessed negative margins because of the heavy investment in R&D and SG&A (selling and general expenses).

2. Profitability Analysis
•Companies with a large portfolio of drugs have seen higher profitability in the pharmaceutical industry.
•The long timelines and accumulating expenditures incurred before a drug is commercialized is making the biotechnology industry less profitable in initial years, even resulting in negative margins for companies that are smaller in terms of revenue.

3. Turnover Analysis
•In both the pharmaceutical and biotechnology industries, companies with lower revenue had poor turnover ratios because of the huge investments made in assets and in the development of the product.

4. Cash Reserve Analysis
•In the pharmaceutical industry the smaller companies in terms of revenue are increasing their cash reserve as a percentage of their assets.
•In the biotechnology industry, both small and large companies in terms of revenue are increasing their cash reserve as a percentage of their assets.

5. R&D to Sales Ratio
•Both the pharmaceutical and biotechnology industries did not witness a great variation in the R&D to sales ratio in 2011 compared to the previous year. Though there was a general decline in the overall sales in both the pharmaceutical and biotechnology industries, the R&D expenses were not considerably reduced.

Who Will Benefit?

•Pharmaceutical & biotechnology companies
•Private equity
•Venture capital investors
•Fund managers
•Retail investors
•Sovereign wealth funds
•Hedge funds
•Insurance funds and other members of the investing community

Table Of Contents

Financial Assessment of the Global Pharmaceutical and Biotechnology Industry 
Table Of Contents

1. Executive Summary

2. Definition of Key Terms

3. Research Objective and Scope

4. Research Methodology

5. Key Issues/Challenges Faced by Industry Participants

6. Pharmaceutical Industry

7. Top Performers in the Pharmaceutical Industry

8. Biotechnology Industry

9. Top Performers in the Biotechnology Industry

10. The Frost and Sullivan Story

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • February 2015
  • by Global Data

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 Summary Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, ...

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research study provides an in-depth analysis and forecast of selected areas of the global healthcare acquired infections (HAI) market. The report offers forecasts by treatment segment and type ...

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

  • $ 6 000
  • Industry report
  • April 2015
  • by Frost & Sullivan

Executive Summary Need for Effective Working Capital Management •Decreasing profitability •Fizzling innovation model •Access to new markets •Price premium pressure Key Trends •The analysis of ...


Download Unlimited Documents from Trusted Public Sources

Drug And Medication Industry in the US

  • June 2015
    45 pages
  • Opioid  

    Analgesic  

    Anesthetics  

  • United States  

View report >

Anesthetics Industry in the US

  • June 2015
    32 pages
  • Anesthetics  

    Vaccine  

  • United States  

    North America  

    World  

View report >

Vitamin And Supplement Industry in Nigeria

  • June 2015
    6 pages
  • Vitamin and Sup...  

  • Nigeria  

    United States  

View report >

Related Market Segments :

Pharmaceutical
Biotechnology

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.